Reid IR, Billington EO (2022) Drug therapy for osteoporosis in older adults. Lancet 399(10329):1080–1092

Article  CAS  PubMed  Google Scholar 

Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM et al (2017) Goal-directed treatment for osteoporosis: A progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 32(1):3–10

Article  CAS  PubMed  Google Scholar 

Marini F, Giusti F, Palmini G, Brandi ML (2023) Role of wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders. Osteoporos Int 34(2):213–238

Article  CAS  PubMed  Google Scholar 

Tabacco G, Bilezikian JP (2019) Osteoanabolic and dual action drugs. Br J Clin Pharmacol 85(6):1084–1094

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532–1543

Article  CAS  PubMed  Google Scholar 

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417–1427

Article  CAS  PubMed  Google Scholar 

Compston JE, Drake MT (2020) Defining very high fracture risk: Is FRAX fit for purpose? J Bone Miner Res 35(8):1399–1403

Article  PubMed  Google Scholar 

Schini M, Johansson H, Harvey NC, Lorentzon M, Kanis JA, McCloskey EV (2024) An overview of the use of the fracture risk assessment tool (FRAX) in osteoporosis. J Endocrinol Invest 47(3):501–511

Article  CAS  PubMed  Google Scholar 

Kobayakawa T, Suzuki T, Nakano M, Saito M, Miyazaki A, Takahashi J et al (2021) Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study. Bone Rep 14:101068

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miyauchi A, Hamaya E, Shimauchi J, Yoshinaga Y, Nishi K (2024) Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: A Japanese real-world study. J Bone Miner Metab 42(1):77–89

Article  CAS  PubMed  Google Scholar 

Inose H, Ariga A, Motoyoshi T, Fukushima K, Tomizawa S, Kato T et al (2022) The real-world effect of 12 months of romosozumab treatment on patients with osteoporosis with a high risk of fracture and factors predicting the rate of bone mass increase: A multicenter retrospective study. JBMR Plus 6(7):e10637

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cosman F, Crittenden DB, Ferrari S, Khan A, Lane NE, Lippuner K et al (2018) FRAME study: The foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab. J Bone Miner Res 33(7):1219–1226

Article  CAS  PubMed  Google Scholar 

Cosman F, Libanati C, Deignan C, Yu Z, Wang Z, Ferrari S et al (2021) Romosozumab followed by antiresorptive treatment increases the probability of achieving bone mineral density treatment goals. JBMR Plus 5(11):e10546

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD et al (2020) Fracture risk and management of discontinuation of denosumab therapy: A systematic review and position statement by ECTS. J Clin Endocrinol Metab 106:264–281

Article  Google Scholar 

McClung MR, Bolognese MA, Brown JP, Reginster JY, Langdahl BL, Maddox J et al (2020) A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int 31(11):2231–2241

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oue T, Shimizu T, Asano T, Shimodan S, Ishizu H, Arita K et al (2023) Comparison of the efficacy of zoledronate acid or denosumab after switching from romosozumab in japanese postmenopausal patients. Calcif Tissue Int 112(6):683–690

Article  CAS  PubMed  Google Scholar 

Lewiecki EM, Betah D, Humbert L, Libanati C, Oates M, Shi Y et al (2024) 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. J Bone Miner Res 39:473–483

Article  PubMed  Google Scholar 

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412–420

Article  CAS  PubMed  Google Scholar 

Genant HK, Engelke K, Bolognese MA, Mautalen C, Brown JP, Recknor C et al (2017) Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass. J Bone Miner Res 32(1):181–187

Article  CAS  PubMed  Google Scholar 

Keaveny TM, Crittenden DB, Bolognese MA, Genant HK, Engelke K, Oliveri B et al (2017) Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res 32(9):1956–1962

Article  CAS  PubMed  Google Scholar 

Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM et al (2018) Remodeling and modeling-based bone formation with teriparatide versus denosumab: A longitudinal analysis from baseline to 3 months in the AVA study. J Bone Miner Res 33(2):298–306

Article  CAS  PubMed  Google Scholar 

Chavassieux P, Chapurlat R, Portero-Muzy N, Roux JP, Garcia P, Brown JP et al (2019) Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: Bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment. J Bone Miner Res 34(9):1597–1608

Article  CAS  PubMed  Google Scholar 

Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S et al (2022) Modeling-based bone formation after 2 months of romosozumab treatment: Results from the FRAME clinical trial. J Bone Miner Res 37(1):36–40

Article  CAS  PubMed  Google Scholar 

Cosman F, Lewiecki EM, Ebeling PR, Hesse E, Napoli N, Matsumoto T et al (2020) T-score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial. J Bone Miner Res 35(7):1333–1342

Article  CAS  PubMed  Google Scholar 

Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F et al (2022) Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone 154:116209

Article  CAS  PubMed  Google Scholar 

McClung MR, Betah D, Deignan C, Shi Y, Timoshanko J, Cosman F (2023) Romosozumab efficacy in postmenopausal women with no prior fracture who fulfill criteria for very high fracture risk. Endocr Pract 29:716–722

Article  PubMed  Google Scholar 

Geusens P, Oates M, Miyauchi A, Adachi JD, Lazaretti-Castro M, Ebeling PR et al (2019) The effect of 1 year of romosozumab on the incidence of clinical vertebral fractures in postmenopausal women with osteoporosis: Results from the FRAME study. JBMR Plus 3(10):e10211

Article  PubMed  PubMed Central  Google Scholar 

Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J et al (2024) Romosozumab in patients who experienced an on-study fracture: Post hoc analyses of the FRAME and ARCH phase 3 trials. Osteoporos Int. https://doi.org/10.1007/s00198-024-07049-w

Article  PubMed  Google Scholar 

Schemitsch EH, Miclau T, Karachalios T, Nowak LL, Sancheti P, Poolman RW et al (2020) A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. JBJS 102(8):693–702

Article  Google Scholar 

Iconaru L, Charles A, Baleanu F, Surquin M, Benoit F, Mugisha A et al (2022) Prediction of an imminent fracture after an index fracture-models derived from the frisbee cohort. J Bone Miner Res 37(1):59–67

Article  CAS  PubMed  Google Scholar 

Kanis JA, Harvey NC, Johansson H, Liu E, Vandenput L, Lorentzon M et al (2020) A decade of FRAX: How has it changed the management of osteoporosis? Aging Clin Exp Res 32(2):187–196

Article  PubMed  Google Scholar 

Porcu G, Biffi A, Ronco R, Adami G, Alvaro R, Bogini R et al (2024) Refracture following vertebral fragility fracture when bone fragility is not recognized: Summarizing findings from comparator arms of randomized clinical trials. J Endocrinol Invest 47(4):795–818

Article  CAS  PubMed  Google Scholar 

Gielen E, Aldvén M, Kanis JA, Borgström F, Senior E, Willems D (2024) Cost-effectiveness of romosozumab for the treatment of postmenopausal women with osteoporosis at high risk of fracture in Belgium. Osteoporos Int. https://doi.org/10.1007/s00198-024-07043-2

Article  PubMed  Google Scholar 

Cosman F, Crittenden DB, Ferrari S, Lewiecki EM, Jaller-Raad J, Zerbini C et al (2018) Romosozumab FRAME study: A post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res 33(8):1407–1416

Article  CAS  PubMed  Google Scholar 

Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R (2020) Pharmacological management of osteoporosis in postmenopausal women: An endocrine society guideline update. J Clin Endocrinol Metab 105(3):587–594

Article  Google Scholar 

Watts NB, Camacho PM, Lewie